Role and Function of A2A and A3 Adenosine Receptors in Patients with Ankylosing Spondylitis, Psoriatic Arthritis and Rheumatoid Arthritis

The A3 adenosine receptor (A3AR): therapeutic target and predictive biological marker in rheumatoid arthritis

(2016) Pnina Fishman et al.   CLINICAL RHEUMATOLOGY

Comparative Effectiveness of Biologic Therapy Regimens for Ankylosing Spondylitis

(2016) Chao Chen et al.   MEDICINE

Adenosine and adenosine receptors in the pathogenesis and treatment of rheumatic diseases

(2016) Bruce N. Cronstein et al.   Nature Reviews Rheumatology

Tailored first-line biologic therapy in patients with rheumatoid arthritis, spondyloarthritis, and psoriatic arthritis

(2016) Fabrizio Cantini et al.   SEMINARS IN ARTHRITIS AND RHEUMATISM

Adenosine as a Multi-Signalling Guardian Angel in Human Diseases: When, Where and How Does it Exert its Protective Effects?

(2016) Pier Andrea Borea et al.   TRENDS IN PHARMACOLOGICAL SCIENCES

Signaling via the NFκB system

(2016) Simon Mitchell et al.   Wiley Interdisciplinary Reviews-Systems Biology and Medicine

Oxidative Stress Relevance in the Pathogenesis of the Rheumatoid Arthritis: A Systematic Review

(2016) Celia María Quiñonez-Flores et al.   Biomed Research International

Adenosine: an endogenous mediator in the pathogenesis of psoriasis

(2015) Moira Festugato   ANAIS BRASILEIROS DE DERMATOLOGIA

New immune cells in spondyloarthritis: Key players or innocent bystanders?

(2015) Koen Venken et al.   BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY

Serum matrix metalloproteinases-3 levels in patients with ankylosing spondylitis

(2015) J.W. Gao et al.   GENETICS AND MOLECULAR RESEARCH

History and Perspectives of A2AAdenosine Receptor Antagonists as Potential Therapeutic Agents

(2015) Delia Preti et al.   MEDICINAL RESEARCH REVIEWS

Non-canonical NF-κB signaling in rheumatoid arthritis: Dr Jekyll and Mr Hyde?

(2015) Ae R Noort et al.   ARTHRITIS RESEARCH & THERAPY

Making the next steps in psoriatic arthritis management: current status and future directions

(2015) Diviya Sritheran et al.   Therapeutic Advances in Musculoskeletal Disease

The interleukin-23/interleukin-17 immune axis as a promising new target in the treatment of spondyloarthritis

(2014) Nataliya Yeremenko et al.   CURRENT OPINION IN RHEUMATOLOGY

Evaluation of circulating levels of inflammatory and bone formation markers in axial spondyloarthritis

(2014) Kenia Rodrigues de Andrade et al.   INTERNATIONAL IMMUNOPHARMACOLOGY

Current and emerging therapeutic strategies for preventing inflammation and aggrecanase-mediated cartilage destruction in arthritis

(2014) Carolyn M Dancevic et al.   ARTHRITIS RESEARCH & THERAPY

Activation of adenosine A2Areceptor reduces osteoclast formation via PKA- and ERK1/2-mediated suppression of NFκB nuclear translocation

(2013) Aránzazu Mediero et al.   BRITISH JOURNAL OF PHARMACOLOGY

Multiple sclerosis lymphocytes upregulate A2Aadenosine receptors that are antiinflammatory when stimulated

(2013) Fabrizio Vincenzi et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

Serological markers in psoriatic arthritis: promising tools

(2013) Roberta Ramonda et al.   EXPERIMENTAL BIOLOGY AND MEDICINE

A2A Adenosine Receptors Are Differentially Modulated by Pharmacological Treatments in Rheumatoid Arthritis Patients and Their Stimulation Ameliorates Adjuvant-Induced Arthritis in Rats

(2013) Fabrizio Vincenzi et al.   PLoS One

Apremilast mechanism of action and application to psoriasis and psoriatic arthritis

(2012) Peter Schafer   BIOCHEMICAL PHARMACOLOGY

Pharmacological and therapeutic effects of A3 adenosine receptor agonists

(2011) Pnina Fishman et al.   DRUG DISCOVERY TODAY

CGS 21680, an agonist of the adenosine (A2A) receptor, decreases acute lung inflammation

(2011) Daniela Impellizzeri et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Adenosine receptor targeting in health and disease

(2011) Stefania Gessi et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

CGS 21680, an Agonist of the Adenosine (A2A) Receptor, Reduces Progression of Murine Type II Collagen-induced Arthritis

(2011) EMANUELA MAZZON et al.   JOURNAL OF RHEUMATOLOGY

A2A and A3 adenosine receptor expression in rheumatoid arthritis: upregulation, inverse correlation with disease activity score and suppression of inflammatory cytokine and metalloproteinase release

(2011) Katia Varani et al.   ARTHRITIS RESEARCH & THERAPY

The role of adenosine receptors in rheumatoid arthritis

(2010) Katia Varani et al.   AUTOIMMUNITY REVIEWS

Adenosine receptors and cancer

(2010) Stefania Gessi et al.   BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES

Immunologic rheumatic disorders

(2010) Amy Joseph et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection

(2009) M Rudwaleit et al.   ANNALS OF THE RHEUMATIC DISEASES

Normalization of A2Aand A3adenosine receptor up-regulation in rheumatoid arthritis patients by treatment with anti-tumor necrosis factor α but not methotrexate

(2009) Katia Varani et al.   ARTHRITIS AND RHEUMATISM

The anti-inflammatory target A3 adenosine receptor is over-expressed in rheumatoid arthritis, psoriasis and Crohn’s disease

(2009) A. Ochaion et al.   CELLULAR IMMUNOLOGY

A2A adenosine receptor overexpression and functionality, as well as TNF-α levels, correlate with motor symptoms in Parkinson’s disease

(2009) Katia Varani et al.   FASEB JOURNAL

The A 3 adenosine receptor agonist CF502 inhibits the PI3K, PKB/Akt and NF-κB signaling pathway in synoviocytes from rheumatoid arthritis patients and in adjuvant-induced arthritis rats

(2008) A. Ochaion et al.   BIOCHEMICAL PHARMACOLOGY

Adenosine receptors: therapeutic aspects for inflammatory and immune diseases

(2008) György Haskó et al.   NATURE REVIEWS DRUG DISCOVERY